»ï¼ºÃ¢¿øº´¿ø Samsung Changwon Gynecologic Oncology Precision Medicine Meeting : 2019-01-19 |
|
»ï¼ºÃ¢¿øº´¿ø Samsung Changwon Gynecologic Oncology Precision Medicine Meeting : 2019-01-19 ±³À°ÀÏÀÚ : 2019-01-19 ±³À°Àå¼Ò : »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç ±³À°ÁÖÁ¦ : Samsung Changwon Gynecologic Oncology Precision Medicine Meeting ÁÖÃÖ±â°ü : »ï¼ºÃ¢¿øº´¿ø ´ã´çÀÚ : ±è¹Î±Ô ¿¬¶ôó : 055-233-5290 À̸ÞÀÏ : minkyu72.kim@samsung.com ±³À°Á¾·ù : »êºÎÀΰú Âü¼®¿¹»óÀοø : 50¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : °æ»ó³²µµ ±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ ¼¼ºÎ¼ö°·á : 70,000¿ø ºñ°í »çÀüµî·Ï: 5¸¸¿ø(Àü°øÀÇ/°£È£»ç 3¸¸¿ø) ÇöÀåµî·Ï: 7¸¸¿ø(Àü°øÀÇ/°£È£»ç 3¸¸¿ø) ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:50~11:55 Opening Remark: À¯Àü¼º ºÎÀÎ ¾Ï ȯÀÚ´Â ¾ÕÀ¸·Î ¾î¶»°Ô Ä¡·á¹ÞÀ» °ÍÀΰ¡? ±è¹Î±Ô(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:55~12:20 Ovary cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:20~12:45 Breast cancer À̼®¿µ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:45~13:10 Non-Ovary/Non-Breast BRCA related cancer À¯ÇåÁ¾(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:10~13:35 Non-EM Gynecologic malignancy ÃÖ¹Îö(Â÷ÀÇ°úÇдë) Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:35~13:40 Discussion, Q & A () ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:40~14:05 Bridging Bench to Clinic:Scientist's Experience in GY Maligancy ÇÑÈñµ¿(°Ç±¹ÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:05~14:30 From ¡°Synthetic lethality¡± till PARPi À̼ºÁ¾(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:30~14:55 Oncologic Urgency/Emergency/Complication Management À̹οµ(¼øõÇâÀÇ´ë) Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:55~15:00 Discussion () ÈÞ½Ä 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:00~15:05 Coffee Break () ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:05~15:30 Pursuit of Better Through Comprehensive Genomic Profiling °¡¼ÒÁ¤(Çѱ¹ ·Î½´) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:30~15:55 Microsatellite instability (MSI) test as a screening for Lynch syndrome and biomarker for Immunotherapy ±èÁ¤¾Æ(ÇÁ·Î¸Þ°¡ ÄÚ¸®¾Æ) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:55~16:20 Germline and somatic mutation tests: the same genes, but not the same testing ÀÌ¿ìâ(¼¿ï¾Æ»êº´¿ø) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:20~16:45 Somatic (Tumor) mutation test has a wider advantage than Germline mutation test ¼ºÃ¢¿Á(¼¿ï¾Æ»êº´¿ø) Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:45~16:50 Discussion, Q & A () ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:50~17:15 When is high time to prepare Survivorship care for Hereditary cancer patients? ½Åµ¿¿í(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:15~17:40 Fertility issue management for Hereditary cancer patients Ȳ±Ô¸®(¼¿ïÀÇ´ë) ±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:40~18:05 Meta-analysis result for Hereditary cancer patients ¼ÛÅÂÁ¾(¼º±Õ°üÀÇ´ë) Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:05~18:10 Discussion () ±âŸ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:10~18:15 Closing Remark ±è¹Î±Ô(¼º±Õ°üÀÇ´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|